NIGERIA—The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a warning about a counterfeit antimalarial drug, Combiart Dispersible Tablet, which is being circulated in Nigeria.
The product, manufactured by Strides Arcolab Limited, an India-based pharmaceutical company, was discovered in the Federal Capital Territory and Rivers State during routine surveillance by NAFDAC officials.
According to the agency’s announcement on X, laboratory tests revealed that the counterfeit product contained no active pharmaceutical ingredients (APIs), which are essential for the drug’s effectiveness.
Additionally, the product was found to have two different date markings, raising further concerns about its authenticity.
NAFDAC also confirmed that the product’s registration number was incorrect, and the product license had expired, making it illegal for sale.
Combiart is a combination of Artemether and Lumefantrine, which are used to treat malaria, a serious infection transmitted through mosquito bites.
However, this medication is not intended for treating severe or complicated malaria. Counterfeit versions, like the one NAFDAC discovered, do not meet the required regulatory standards and pose significant health risks.
These fake drugs can fail to treat the intended condition and may lead to severe health complications or even death.
NAFDAC further stated that the affected batches of the counterfeit product have the batch number 7225119 and a registration number of A11-0299.
The products in question were manufactured in June and February of 2023, with expiry dates set for May and June 2026.
NAFDAC has instructed its zonal directors and state coordinators to increase surveillance and remove any counterfeit products from the market.
The agency strongly advises the public, healthcare professionals, and consumers to remain vigilant when purchasing medical products.
Only products from licensed and authorized suppliers should be used, and the authenticity of the products should be carefully verified.
It is crucial to check the packaging, registration numbers, and expiry dates to avoid using substandard medications.
Consumers who suspect they have encountered counterfeit drugs are urged to report them to the nearest NAFDAC office.
NAFDAC has also set up various reporting channels, including an online platform for adverse event reporting on its website, and the Med-Safety app, which can be downloaded on Android and iOS devices.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
